Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection

In recent reports, IRF5 polymorphisms showed significant association with multiple sclerosis (MS) susceptibility in three studied populations and Irf5-deficient mice exhibited an increased susceptibility to viral infection, linked to a significant decrease in the induction of serum type I interferon (IFN). In the present study, we evaluated the association of two IRF5 polymorphisms with MS predisposition and we also addressed whether these polymorphisms were associated with active replication of human herpes virus-6 (HHV-6) observed in a subgroup of MS patients, and/or with response to IFN-β therapy. A total of 1494 MS patients and 1506 ethnically matched controls were genotyped for rs4728142 and rs3807306 with TaqMan pre-designed assays. One hundred and six patients were classified as responders to IFN-β therapy (no relapses/increases in EDSS over the 2-year follow-up) and 112 as non-responders (at least two relapses or an increase in expanded disability status scale (EDSS) of at least one point during the same period). The combined analysis of available datasets yielded an effect size on MS with odds ratio (OR)Mantel−Haenszel=1.14 (P<0.002) for the IRF5 polymorphisms rs4728142 and rs3807306. Additionally, trends for association were observed between rs3807306T and infection with HHV-6 [p=0.05, OR (95% CI)=1.56 (1.00–2.44)] and response to IFN-β therapy [P=0.09, OR (95% CI)=1.39 (0.95–2.05)].

[1]  C. Verweij,et al.  Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. , 2009, Pharmacogenomics.

[2]  Carey L. Medin,et al.  Functional Characterization of Murine Interferon Regulatory Factor 5 (IRF-5) and Its Role in the Innate Antiviral Response* , 2008, Journal of Biological Chemistry.

[3]  L. Milani,et al.  An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. , 2007, Human molecular genetics.

[4]  D. Hillyard,et al.  Use of lyophilized standards for the calibration of a newly developed real time PCR assay for human herpes type six (HHV6) variants A and B. , 2005, Journal of virological methods.

[5]  L. O’Neill,et al.  Targeting signal transduction as a strategy to treat inflammatory diseases , 2006, Nature Reviews Drug Discovery.

[6]  Tak W. Mak,et al.  Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors , 2005, Nature.

[7]  X. Mariette,et al.  Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. , 2007, Arthritis and rheumatism.

[8]  J. Picazo,et al.  Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. , 2004, Archives of neurology.

[9]  H. Hartung,et al.  Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response , 2002 .

[10]  A. Verma,et al.  Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study , 2008 .

[11]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[12]  M. Barro,et al.  Rotavirus NSP1 Inhibits Expression of Type I Interferon by Antagonizing the Function of Interferon Regulatory Factors IRF3, IRF5, and IRF7 , 2007, Journal of Virology.

[13]  K. Honda,et al.  Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression , 2007, Proceedings of the National Academy of Sciences.

[14]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[15]  P. Pitha,et al.  Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. , 2003, Cancer research.

[16]  Y. H. Lee,et al.  Functional polymorphisms in matrix metalloproteinase-1 and monocyte chemoattractant protein-1 and rheumatoid arthritis. , 2003, Scandinavian journal of rheumatology.

[17]  P. Moore,et al.  Virus-specific Activation of a Novel Interferon Regulatory Factor, IRF-5, Results in the Induction of Distinct Interferon α Genes* , 2001, The Journal of Biological Chemistry.

[18]  S. Jacobson,et al.  Human herpesvirus 6 and multiple sclerosis: potential mechanisms for virus-induced disease. , 2005, Herpes : the journal of the IHMF.

[19]  J. Hiscott.  Triggering the Innate Antiviral Response through IRF-3 Activation* , 2007, Journal of Biological Chemistry.

[20]  W. Siegert,et al.  Human herpesvirus 6A DNA Is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. , 2001, The Journal of infectious diseases.

[21]  S. Hanash,et al.  Global and Distinct Targets of IRF-5 and IRF-7 during Innate Response to Viral Infection* , 2004, Journal of Biological Chemistry.

[22]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[23]  L. Peltonen,et al.  Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations , 2008, Journal of Medical Genetics.

[24]  Y. Okada,et al.  A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population , 2008, Annals of the rheumatic diseases.

[25]  P. Villoslada,et al.  Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. , 2007, Cytokine & growth factor reviews.

[26]  Pablo Moscato,et al.  Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 , 2009, Nature Genetics.

[27]  Javier Martín,et al.  Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. , 2006, Arthritis & Rheumatism.

[28]  J. M. Henry,et al.  Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  N. Rohland,et al.  The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5* , 2009, Journal of Biological Chemistry.

[30]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[31]  R. Cantor,et al.  Association of IRF5 polymorphisms with activation of the interferon α pathway , 2009, Annals of the rheumatic diseases.

[32]  O. Kantarci.  Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures , 2009 .

[33]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[34]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.